Status:

RECRUITING

Observational Study of Efficiency of Cytoflavin, in Patients With Ischemic Stroke Not Receiving Reperfusion Therapy

Lead Sponsor:

POLYSAN Scientific & Technological Pharmaceutical Company

Conditions:

Stroke, Acute

Stroke, Ischemic

Eligibility:

All Genders

18+ years

Brief Summary

Stroke remains one of the main socially significant problems in the healthcare in the third millennium. The lethality in persons with history of stroke by the end of the 1st year of disease is high. A...

Eligibility Criteria

Inclusion

  • Signed informed consent form
  • Age from 18 years and older
  • Diagnosis: Acute cerebrovascular accident of ischemic type (ischemic stroke) developed within 36 hours before enrollment in the study
  • Motor neurologic deficit measurable using the NIHSS Scale (score for item 5 and/or 6 at the time of starting the therapy ≥ 1))
  • Conservative stroke treatment tactics (without reperfusion therapy thrombolysis/thrombus extraction)
  • According to the routine clinical practice, the patient is scheduled to receive the treatment as per one of the following regimens:
  • Cytoflavin® 20-40 ml/day as a course of not less than 10 days or
  • another neuroprotector - course of not less than 10 days (or without neuroprotector)

Exclusion

  • NIHSS 1a (coma) score 3 at the time of enrollment
  • Initial severe disablement (corresponding to mRS \> 2) requiring external assistance in everyday life before development of stroke
  • History of Parkinson's disease, dementia, multiple sclerosis, and other significant diseases accompanied by neurologic deficit
  • Severe comorbidity with expected lifespan of not more than 6 months
  • Pregnancy and breastfeeding
  • Any other concomitant medical or serious psychic conditions, which make the patient ineligible for participation in the study, restrict lawfulness of obtaining the informed consent, or can influence the patient's ability to participate in the study

Key Trial Info

Start Date :

March 1 2024

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

November 1 2025

Estimated Enrollment :

562 Patients enrolled

Trial Details

Trial ID

NCT06514976

Start Date

March 1 2024

End Date

November 1 2025

Last Update

April 18 2025

Active Locations (17)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 5 (17 locations)

1

"Ivanovo Regional Clinical Hospital"

Ivanovo, Russia

2

Kazan State Medical University

Kazan', Russia

3

State Autonomous Institution of Health Interregional clinical diagnostic center

Kazan', Russia

4

Moscow City Clinical Hospital No.64 (CCH named after V.V. Vinogradov)

Moscow, Russia